

**IKS HEALTH**  
 QUALITY PRACTICE. QUALITY CARE.  
**INVENTURUS KNOWLEDGE SOLUTIONS LIMITED**  
 (formerly known as Inventurus Knowledge Solutions Private Limited)  
 CIN: L72200MH2008PLC337651  
 Registered office: 801, Building No 5 & 6, 8th Floor, Mindspace Business Park (SEZ), Thane - Belapur Road, Andri, New Mumbai - 400 708, Thane, Maharashtra, India.  
 Telephone : +91 22 3964 3205  
 Website: www.ikshealth.com Email: investor\_relations@ikshealth.com

**EXTRACT OF THE STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024**  
 (Amounts in INR Million, unless otherwise stated)

S. No.	Particulars	For the quarter ended		For the nine months ended	
		December 31, 2024	December 31, 2024	December 31, 2024	December 31, 2023
1.	Revenue from operations	6,571.81	19,400.38	5,670.95	
2.	Profit before tax	1,601.55	4,261.97	1,236.79	
3.	Profit for the period	1,296.75	3,382.58	1,015.37	
4.	Total Comprehensive Income for the period	1,344.01	3,434.44	1,056.75	
5.	Paid-up equity share capital (Face value ₹ 1 per share)	169.77	169.77	169.08	
6.	Reserves excluding revaluation reserves as at balance sheet date*	11,409.38	11,409.38	8,118.03	
7.	Earnings per share (Nominal value of share ₹ 1 each)				
	Basic (INR per share)	7.80	20.35	6.14	
	Diluted (INR per share)	7.60	19.84	6.07	

\*Balances for quarter and nine months ended December 31, 2024 represent balances as per the audited consolidated balance sheet for the year ended March 31, 2024 and balances for quarter months ended December 31, 2023 represent balances as per the audited consolidated balance sheet for the year ended March 31, 2023 as required by Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

**EXTRACT OF THE STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2024**  
 (Amounts in INR Million, unless otherwise stated)

S. No.	Particulars	For the quarter ended		For the nine months ended	
		December 31, 2024	December 31, 2024	December 31, 2024	December 31, 2023
1.	Revenue from operations	2,413.13	6,827.16	2,503.44	
2.	Profit before tax	986.74	2,811.59	1,327.19	
3.	Profit for the period	827.74	2,321.39	1,129.60	
4.	Total Comprehensive Income for the period	678.91	2,144.35	1,138.67	

**Notes:**  
 1. The above standalone financial results of Inventurus Knowledge Solutions Limited ("the Company") and consolidated financial results of the Company and its subsidiaries (collectively "the Group") for the quarter and nine months ended December 31, 2024 were reviewed and recommended by the Audit Committee and approved by the Board of Directors in its meeting held on February 5, 2025. The above results for the quarter and nine months ended December 31, 2024 have been reviewed by the Statutory Auditors of the Company in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended. The figures for the quarter ended September 30, 2024, corresponding quarter ended December 31, 2023 and corresponding nine months ended December 31, 2023 as reported in the statement have been approved by the Company's Board of Directors but have not been subjected to limited review since the requirement of submission of quarterly consolidated financial results is applicable on listing of equity shares of the Company from the quarter ended December 31, 2024.  
 2. The above is an extract of the detailed format of financial results filed with Stock Exchanges under Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format for quarter and nine months ended December 31, 2024, available on the Company's website (URL: <https://www.ikshealth.com/investor-relations/>). The same can be accessed by scanning the QR code provided below.

**For Inventurus Knowledge Solutions Limited**  
 Sachin Gupta  
 Whole-Time Director  
 DIN - 02239277

Place : Mumbai  
 Date : February 5, 2025

Affidavit: 598/25

**ICICI Prudential Asset Management Company Limited**  
 Corporate Identity Number: U99999DL1993PLC054135  
 Registered Office: 12<sup>th</sup> Floor, Narain Manzil, 23, Barokhamba Road, New Delhi - 110 001.  
 Corporate Office: ONE BKC, A - Wing, 13<sup>th</sup> Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051. Tel: +91 22 2652 5000, Fax: +91 22 2652 8100, Website: www.icicipruamc.com, Email id: enquiry@icicipruamc.com  
 Central Service Office: 2<sup>nd</sup> Floor, Block B-2, Niroun Knowledge Park, Western Express Highway, Goregaon (E), Mumbai - 400 063. Tel: 022 2689 2000 Fax: 022 26868313

**Notice to the Investors/Unit holders of ICICI Prudential Bond Fund, ICICI Prudential Banking & Financial Services Fund and ICICI Prudential MNC Fund (the Schemes)**  
 Notice is hereby given that ICICI Prudential Trust Limited, Trustee to ICICI Prudential Mutual Fund has approved the following distribution under Income Distribution cum Capital Withdrawal option (IDCW option) of the Schemes, subject to availability of distributable surplus on the record date i.e. on February 11, 2025:

Name of the Schemes/Plans	Quantum of IDCW (₹ per unit) (Face value of ₹ 10/- each) <sup>1</sup>	NAV as on February 5, 2025 (₹ Per unit)
<b>ICICI Prudential Bond Fund</b>		
IDCW Quarterly	0.2100	11.5322
Direct Plan - IDCW Quarterly	0.2288	11.9196
<b>ICICI Prudential Banking &amp; Financial Services Fund</b>		
IDCW	5.70	33.85
Direct Plan - IDCW	5.70	72.91
<b>ICICI Prudential MNC Fund</b>		
IDCW	1.75	19.16
Direct Plan - IDCW	1.75	21.03

5. The distribution will be subject to the availability of distributable surplus and may be lower depending upon the extent of distributable surplus available on the record date under the IDCW option of the Schemes.  
 # Subject to deduction of applicable statutory levy, if any  
 \* or immediately following Business Day, if that day is a Non - Business Day.  
 The distribution with respect to IDCW will be done to all the unit holders/beneficial owners whose names appear in the register of unit holders/Statement of beneficial owners maintained by the Depositories, as applicable under the IDCW option of the Schemes, at the close of business hours on the record date.  
**It should be noted that pursuant to payment of IDCW, the NAV of the IDCW option of the Schemes would fall to the extent of payout and statutory levy (if applicable).**

For ICICI Prudential Asset Management Company Limited  
 Place: Mumbai  
 Date: February 6, 2025  
 No. 002/02/2025

**To know more, call 1800 222 999/1800 200 6666 or visit [www.icicipruamc.com](http://www.icicipruamc.com)**  
 Investors are requested to periodically review and update their KYC details along with their mobile number and email id.  
 To increase awareness about Mutual Funds, we regularly conduct Investor Awareness Programs across the country. To know more about it, please visit <https://www.icicipruamc.com> or visit AMFI's website <https://www.amfiindia.com>  
**Mutual Fund investments are subject to market risks, read all scheme related documents carefully.**

**Gujarat State Petronet Limited**  
 Corporate Identity Number: LA2200GJ1995G030188  
 Regd. Office: GSPC Bhavan, Sector-11, Gandhinagar-382011, Gujarat.  
 Tel.: +91-79-23268507/06 Fax: +91-79-23268506 Website: www.gspcgroup.com  
**NOTICE INVITING TENDER**  
 Gujarat State Petronet Limited (GSPNL) is laying a gas grid, to facilitate gas transmission from supply points to demand centers across Gujarat. GSPNL invites bids from reputed pipeline construction companies for following requirements: 'Single Stage, Three-Part' open bidding process:  
 Tender-1: Pipeline and Associated works for Jamnagar-Dwarka Pipeline Project (18"x88 Km approx.) on EPC basis  
 Tender-2: Pipeline and Associated works for Vantavaj-Rajpipla Pipeline Project (18"x44 Km approx.) on EPC basis  
 Tender-3: Pipeline and Associated works for Bhaya Connectivity Pipeline Project (12"x31 Km approx.) on EPC basis

Aftermentioned tenders shall be published online through e-Procure, and bids are accepted through e-Procure (<https://gspnlender.nprocure.com/>) only. Date of tender upload on e-Procure portal is 07-02-2025 at 15.00 hrs. IST

**GREENLIME INDUSTRIES LIMITED**  
 Registered & Corporate Office: 203, 2<sup>nd</sup> Floor, West Wing, Worldmark 3, Arundel, 52, Bayview, Worshipping, Borealis, Mumbai - 400 072, India.  
 Phone No. : +91-11-4279-1599, CIN: L21014DL2013PLC236645  
 Email: investor.relations@greenlime.com Website: www.greenlimeindustries.com

**Notice of Postal Ballot and e-voting information to the Members**  
 Notice is hereby given that pursuant to Section 109 and 110 of the Companies Act, 2013 ("Act, 2013"), read with Rule 20 and 22 of the Companies (Management and Administration) Rules, 2014 and other applicable provisions, if any, of the Act, 2013 (including any statutory modification or re-enactment thereof for the time being in force), the Securities and Exchange Board of India (Listing and Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") and the Secretarial Standards on General Meeting issued by the Institute of Company Secretaries of India read with the General Circular No. 14/2020 dated April 8, 2020, 17/2020 dated April 13, 2020, latest Circular No. 09/2024 dated September 19, 2024 and other applicable Circulars issued by Ministry of Corporate Affairs ("MCA") and Securities and Exchange Board of India ("SEBI") (hereinafter collectively referred to as "Circulars") and other applicable laws and regulations, if any, the approval of the Members of the Company is being sought by way of Postal Ballot for special businesses as set out below and in the Postal Ballot Notice dated January 30, 2025 together with the explanatory statement pursuant to Section 102 of the Act, 2013, relating thereto.

Sr.	Description of Resolution	Type of Resolution
1.	Issue of Bonus Shares	Ordinary Resolution
2.	Increase in Authorized Share Capital and consequent alteration to the Capital Clause of the Memorandum of Association	Ordinary Resolution

The Company has completed the dispatch of the Postal Ballot Notice along with the explanatory statement pursuant to Section 102 of the Act, 2013 on February 6, 2025, by e-mail to those Members whose e-mail addresses were registered with the Company/Depositories as on January 31, 2025. In terms of the above said Circulars, the requirement of sending the physical Notice of Postal Ballot along with the Postal Ballot Form has been dispensed with.  
 The communication of the assent or dissent of the Members on the resolution would take place through the Remote e-voting system only. In this regard, the Company has engaged Link Intime India Private Limited ("Link Intime India Private Limited") (Formerly known as Link Intime India Private Limited) providing the Remote e-voting facility to the Members. The Members may note that this Postal Ballot Notice will also be available on the Company's website, at [www.greenlimeindustries.com](http://www.greenlimeindustries.com) and websites of stock exchanges i.e. National Stock Exchange of India Limited, at [www.nseindia.com](http://www.nseindia.com) and BSE Limited where the equity shares of the Company are listed, at [www.bseindia.com](http://www.bseindia.com) and on the website of MUFGL Intime India Private Limited, at <https://intstave.lintime.com>.  
 The voting rights of the Members shall be in proportion to the shares held by them in the paid-up equity share capital of the Company as on Friday, January 31, 2025 ("Cut-off date"). Only those Members whose names are recorded in the Register of Members of the Company or in the Register of Beneficial Owners maintained by the Depositories as on the Cut-off date will be entitled to cast their votes by Remote e-voting. A person who is not a Member as on the Cut-off date should treat this Notice for information purposes only. The Remote e-voting period will commence from 09.00 a.m. (IST) on Sunday, February 9, 2025 and will end at 5.00 p.m. (IST) on Monday, March 10, 2025 (Voting Period). After the conclusion of the Voting Period, the Remote e-voting module shall be disabled by MUFGL Intime India Private Limited and accordingly, the voting shall not be allowed. Once the vote on the resolution is cast by the Member, he/she shall not be allowed to change it subsequently. Those Members whose e-mail address is not registered with the Company / Depositories, may register the same by completing the process for registration of the same as under:

Sl. No.	Particulars	Standalone			Consolidated		
		31 Dec 2024	30 Sep 2024	31 Dec 2023	31 Dec 2024	30 Sep 2024	31 Dec 2023
1	Total income from operations	3,374.07	3,283.49	3,831.53	9,830.31	14,441.19	10,104.11
2	Net Profit (Loss) for the period (before tax, Exceptional and Extraordinary items)	548.91	616.20	434.57	1,707.82	-357.94	878.87
3	Net Profit (Loss) for the period before tax (after Exceptional and Extraordinary items)	548.91	616.20	434.57	1,707.82	-358.94	-1,028.33
4	Net Profit (Loss) for the period after tax (after Exceptional and Extraordinary items)	411.88	503.86	293.43	1,334.09	-1,075.83	-1,654.51
5	Total Comprehensive Income for the period (Comprising Profit/Loss for the period (after tax) and Other Comprehensive Income (after tax))	413.61	499.29	271.74	1,333.95	-1,099.58	-1,676.26
6	Equity Share Capital	306.21	306.21	286.13	286.13	306.21	306.21
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year	-	-	-	-	1,152.95	-
8	Earnings Per Share (EPS) (of Rs. 2/- each) <sup>1</sup>						
	1. Basic:	2.69	3.38	2.05	8.99	-7.52	-11.56
	2. Diluted:	2.69	3.38	2.05	8.99	-7.52	-11.56

**Notes:**  
 a) The above is an extract of the detailed format of Financial Results for the quarter and nine months period ended 31 December 2024 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended). The full format of the Standalone and Consolidated Financial Results are available on the website of the Stock Exchange(s) and the listed entity, www.akums.in  
 b) The above Standalone and Consolidated Financial Results for the quarter and nine months period ended 31 December 2024 have been reviewed and recommended by the Audit Committee on 6 February 2025 and approved by the Board of Directors at their meetings held on 6 February 2025. The statutory auditors have expressed an unmodified review conclusion on these results.  
 c) The figures for the quarter ended 31 December 2023 are the balancing figures between the management certified year to date figures upto the nine months period ended 31 December 2023 and audited year to date figures upto six months period ended 30 September 2023 extracted from the audited Special Purpose Standalone Interim Statement of Profit and Loss for the six months period ended 30 September 2023.  
 d) Akums Drugs and Pharmaceuticals Limited (the Company, "Holding Company") in earlier years, executed a shareholders' agreement (the "Agreement") with its promoters (Mr. Sandeep Jain and Mr. Sanjeev Jain) and Ruby OC Investments Pte. Limited (the "Investor") wherein the Investor was given the right to require the Company to buyback its equity shares at fair market value in case the Company and/or its promoters were not able to facilitate exit to the Investor through an initial public offer or through a secondary sale to a third party. This was recorded as a put option liability in the books of accounts and was fair valued at each reporting period in accordance with applicable Indian Accounting Standards. This adjustment was recorded as fair value changes to the financial instrument in the standalone and consolidated financial results of the Company, thereby impacting the profit for the period/year, which has been summarised below:

Particulars	Quarter ended		Nine months period ended		Year ended
	31 Dec 2024	30 Sep 2024	31 Dec 2023	31 Dec 2024	31 March 2024
Fair value changes to financial instruments	-	-	188.98	-38.67	3,577.74

However, on 29 May 2024, the Investor has waived off these rights in entirety and post this the Company is no longer required to buy-back the equity shares held by the investor. Hence, the fair value changes has been recorded in these standalone financial results till 29 May 2024 amounting to ₹ 38,677 million (reversal) and the put option liability existing as on the date of waiver i.e. 29 May 2024 amounting to ₹ 13,615.12 million has been reclassified from financial liabilities to other equity thereby increasing the net worth.

For Akums Drugs and Pharmaceuticals Limited  
 Sd/-  
 Sanjeev Jain  
 DIN: 00323433

Sd/-  
 Sandeep Jain  
 DIN: 00323476

Date: New Delhi  
 Place: 6 February 2025

